InstalabLoading...
InstalabLoading...
Most people never think about the specific bacteria living in their gut, but some species are starting to look more like risk factors than passive passengers. Morganella, particularly the species Morganella morganii, sits in this category. It is a normal resident of the human gut for many people, but higher levels have been tied to mood disorders and to opportunistic infections elsewhere in the body.
This test measures how much Morganella is present in your stool. The result is one piece of a broader microbiome picture, and emerging research is beginning to connect this organism to outcomes that have nothing to do with classic digestive symptoms.
Morganella is a genus in the Morganellaceae family, closely related to Proteus and Providencia. The most clinically studied species is M. morganii (Morganella morganii). It lives in the gut of healthy people and in the wider environment, and is generally described as a commensal, meaning it cohabits with you without causing problems most of the time.
The shift from harmless resident to problem occurs when Morganella escapes the gut or grows out of balance. It has been documented as a cause of bloodstream infections, urinary tract infections, wound and surgical infections, and prosthetic joint infections, mostly in older adults or people with weakened immune systems. These infections are clinical events, not direct measurements of gut abundance, but they show why an outsized presence of this microbe can matter.
The most striking finding tying gut Morganella to a long-term outcome comes from a population study of about 6,000 adults followed for up to 16 years. People with higher Morganella abundance in stool had a higher risk of developing major depression, with each standard-deviation rise in Morganella raising future depression risk by about 11% (hazard ratio 1.11). Genetic analysis in the same cohort suggested this link may be causal rather than coincidental, with variation at a gene called PDE1A connecting host biology to gut Morganella levels.
Earlier work cited in the same paper found that people with depression mounted stronger immune responses against a component of Morganella's outer wall (called lipopolysaccharide, a part of certain bacterial membranes that the immune system reacts to). The picture that emerges is a possible gut-to-brain pathway: more Morganella, more immune activation, more depressive risk over time.
While stool-based research on Morganella and infection is sparse, clinical data on people who develop Morganella infections is informative. A multicenter Australian study of 709 bloodstream infections found that Morganella morganii infections are rising, especially in older adults with chronic illness, with about 21% of cases dying within 30 days. Common starting points for these infections were the urinary tract, the skin and soft tissue, and the abdomen.
The research does not directly show that high gut Morganella causes these infections. The evidence connects clinical isolates from sick people to outcomes, not stool levels in healthy adults. Still, the gut is the recognized reservoir for this organism, and people who carry larger amounts may have more opportunity for translocation, particularly during illness, hospitalization, or immune suppression.
Morganella carries an intrinsic enzyme called AmpC beta-lactamase (a built-in defense against several common penicillin and cephalosporin antibiotics). That means standard front-line antibiotics often do not work against it. Multidrug-resistant strains, including those carrying NDM-1 (a gene that disables carbapenem antibiotics, the heavy hitters used for severe infections), have been documented globally. Most isolates still respond to carbapenems, piperacillin/tazobactam, and certain aminoglycosides, but resistance varies widely by region.
If you ever develop a Morganella infection, this matters: empiric antibiotic choices that work for typical urinary or wound infections may fail. Knowing you are a carrier ahead of time gives clinicians a head start.
There are no standardized clinical cutpoints for gut Morganella abundance. The research that links higher levels to depression used standard-deviation comparisons within a single cohort, not absolute thresholds you can apply to your own report. Different stool testing platforms quantify bacteria differently (some report colony-forming units per gram, others report relative abundance from sequencing), so numbers from one lab cannot be directly compared to another.
Treat any number you receive as a starting point, not a verdict. Compare results within the same lab over time to see whether your levels are trending up, down, or holding steady.
Because Morganella levels in stool are influenced by recent diet, antibiotics, and natural day-to-day variation, a single reading is a snapshot, not a verdict. The depression-risk research used population-level comparisons across thousands of adults, which means individual interpretation requires multiple data points to be useful.
Get a baseline now, retest in 3 to 6 months if you make significant changes (new diet, finished an antibiotic course, started a probiotic protocol), and at minimum once a year if you are tracking microbiome trends. The trajectory matters more than any single number.
There is no published intervention proven to lower gut Morganella specifically, so the most useful next step is to look at the result alongside other markers. Pair it with a broader microbiome workup that captures overall dysbiosis, inflammation markers like calprotectin, and short-chain fatty acid output. If you have recurrent urinary tract infections, unexplained mood changes, or a history of opportunistic infections, share the result with a gastroenterologist or infectious disease specialist who works with microbiome data. Retest after any major change to confirm the result is stable rather than a one-time anomaly.
Morganella Species is best interpreted alongside these tests.